Vanguard Group Inc. Buys 6,672 Shares of Biohaven Ltd. $BHVN

Vanguard Group Inc. grew its stake in Biohaven Ltd. (NYSE:BHVN) by 0.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,420,792 shares of the company’s stock after purchasing an additional 6,672 shares during the quarter. Vanguard Group Inc. owned approximately 8.25% of Biohaven worth $202,436,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Janus Henderson Group PLC raised its position in shares of Biohaven by 12.1% in the fourth quarter. Janus Henderson Group PLC now owns 6,982,425 shares of the company’s stock valued at $260,735,000 after purchasing an additional 756,032 shares during the period. Suvretta Capital Management LLC raised its position in shares of Biohaven by 8.1% in the fourth quarter. Suvretta Capital Management LLC now owns 5,620,271 shares of the company’s stock valued at $209,917,000 after purchasing an additional 421,052 shares during the period. Farallon Capital Management LLC raised its position in shares of Biohaven by 21.6% in the fourth quarter. Farallon Capital Management LLC now owns 4,428,167 shares of the company’s stock valued at $165,392,000 after purchasing an additional 785,578 shares during the period. Brown Advisory Inc. raised its position in shares of Biohaven by 4.6% in the first quarter. Brown Advisory Inc. now owns 1,020,117 shares of the company’s stock valued at $24,524,000 after purchasing an additional 44,532 shares during the period. Finally, Nuveen Asset Management LLC raised its position in shares of Biohaven by 55.1% in the fourth quarter. Nuveen Asset Management LLC now owns 919,235 shares of the company’s stock valued at $34,333,000 after purchasing an additional 326,636 shares during the period. 88.78% of the stock is owned by institutional investors.

Biohaven Trading Down 5.3%

Shares of Biohaven stock opened at $15.16 on Wednesday. The company has a market capitalization of $1.60 billion, a price-to-earnings ratio of -1.98 and a beta of 0.98. The company has a quick ratio of 3.82, a current ratio of 3.82 and a debt-to-equity ratio of 1.91. Biohaven Ltd. has a 12-month low of $12.79 and a 12-month high of $55.70. The firm’s 50-day moving average price is $14.45 and its two-hundred day moving average price is $21.51.

Biohaven (NYSE:BHVN) last posted its quarterly earnings results on Monday, August 11th. The company reported ($1.94) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.94). On average, analysts forecast that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on BHVN shares. Bank of America lowered their price target on shares of Biohaven from $50.00 to $49.00 and set a “buy” rating on the stock in a research report on Tuesday, August 12th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target (down from $54.00) on shares of Biohaven in a research report on Tuesday, August 12th. BTIG Research raised their price target on shares of Biohaven from $59.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday. JPMorgan Chase & Co. lowered their price target on shares of Biohaven from $68.00 to $55.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 18th. Finally, Leerink Partners lowered their price target on shares of Biohaven from $60.00 to $50.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 12th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, Biohaven has an average rating of “Buy” and a consensus price target of $54.23.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.